BeneChill Inc. raised $600,000 out of a proposed $1.2 million, according to a Securities & Exchange Commission filing.
The San Diego-based company manufactures a "therapeutic hypothermia" device called the RhinoChill designed to prevent brain damage in patients experiencing cardiac arrest. The system uses a nasal catheter to deliver a coolant to the nasal cavity to reduce patient temperature, according to the company.
The debt financed round is supported by seven unnamed investors with no minimum investment, according to the filing.
The company raised $13.7 million in a Series C venture round in July 2009, according to a filing. BeneChill said (PDF) the Series C funding came from MedVenture Associates, NGN Capital, HealthCap and the Solon Foundation.
BeneChill, which received a CE Mark approval for its RhinoChill system in Europe in January, named Amgen executive director Alan Raffensperger as its CEO in June.
